Disclosed are compositions comprising a Gram negative needle tip protein and a translocator protein and methods of their use.

Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-linker-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.

The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

A generic inert bio-vector Salmonella sp. S9H and potential uses thereof are provided. The generic inert bio-vector Salmonella sp. S9H is derived from a continuous in-vitro culture of an inert bio-vector bacterium Salmonella sp. S9 by using LB solid and liquid culture media for passage to the fortieth generation. With a quantity of bacteria at a working concentration, the S9H does not cause non-specific agglutination reactions in sera or whole blood derived from humans, mice, cattle, pigs and poultry (including chickens, ducks, geese, turkeys, pigeons and quails); moreover, S9H has a property of carrying, and expressing and displaying different antigen factors derived from humans, mice, cattle, pigs and poultry (including chickens, ducks, geese, turkeys, pigeons and quails) on the surface thereof .

Provided are attenuated immunostimulatory bacteria with genomes that are modified to, for example, reduce toxicity and improve the anti-tumor activity, such as by increasing accumulation in the tumor microenvironment, particularly in tumor-resident myeloid cells, improving resistance to complement inactivation, reducing immune cell death, promoting adaptive immunity, and enhancing T-cell function. The increase in colonization of phagocytic cells improves the delivery of encoded therapeutic products to the tumor microenvironment and tumors, and permits, among other routes, systemic administration of the immunostimulatory bacteria.

The present invention relates to a chimeric recombinant protein having a therapeutic effect on cervical cancer by fusing genetic modified E6 and E7, which are carcinogenesis-inducing proteins of human papillomavirus high-risk group type 16, with a fusion protein for increasing immunogenicity, the HPV type 16 E6, E7 chimeric recombinant protein fused with the flagellin fusion protein of the present invention showed the lowest tumor cell volume, and the immune response of specific T cells according to the recombinant antigen was significantly confirmed, and when the prophylactic effect was measured, it was confirmed that the volume of tumor cells was low and the antibody titer was increased, therefore human papillomavirus recombinant antigen of the present invention shows tumor treatment and prophylaxis and can be applied as a therapeutic/prophylactic vaccine composition.

One embodiment provides an attenuated Salmonella strain comprising a lysis gene or cassette operably linked to an intracellularly induced Salmonella promoter. In one embodiment, the promoter is a promoter for one of the genes in Salmonella pathogenicity island 2 type III secretion system (SPI2-T3SS) selected from the group SpiC/SsaB, SseF, SseG, SseI, SseJ, SseK1, SseK2, SifA, SifB, PipB, PipB2, SopD2, GogB, SseL, SteC, SspH1, SspH2, or SirP. In one embodiment, a Salmonella gene is under the regulation of an inducible promoter, wherein the gene is selected from ftsW, ftsA, ftsZ, murE, mukF, imp, secF, eno, hemH, tmk, dxs, uppS, cdsA, accA, pssA, msbA, tsf, trmD, cca, infB, rpoA, rpoB, rpoC, holA, dnaC, or eng. In one embodiment, the Salmonella strain further comprises a plasmid that expresses DNA, shRNA, non-coding RNA and/or a peptide.

Phosphoethanolamine cellulose and methods of making and using it are disclosed. In particular, the invention relates to a method of producing a phosphoethanolamine cellulose biosynthetically using a BcsG phosphoethanolamine transferase for cellulose modification. Recombinant constructs encoding BcsG are described, including constructs encoding BcsG by itself or in combination with BcsE and BcsF, which increase the extent of cellulose modification and the amount of modified cellulose produced. Production of phosphoethanolamine cellulose in cell culture and derivatization of phosphoethanolamine cellulose are also described.